JO3412B1 - أجسام مضادة ل angptl3 واستخداماتها - Google Patents

أجسام مضادة ل angptl3 واستخداماتها

Info

Publication number
JO3412B1
JO3412B1 JOP/2012/0155A JOP20120155A JO3412B1 JO 3412 B1 JO3412 B1 JO 3412B1 JO P20120155 A JOP20120155 A JO P20120155A JO 3412 B1 JO3412 B1 JO 3412B1
Authority
JO
Jordan
Prior art keywords
span
dir
ltr
diseases
disorders
Prior art date
Application number
JOP/2012/0155A
Other languages
English (en)
Inventor
J Murphy Andrew
W Sleeman Mark
Gusarova Viktoria
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3412(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3412B1 publication Critical patent/JO3412B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير جسم مضاد بشري كامل أو شظية رابطة لمولد الضد من الجسم المضاد التي ترتبط بشكل خاص وتثبط أو تتداخل مع نشاط واحد على الأقل لبروتين شبيه بأنجيوبيوتين بشري 3 (<span dir="LTR">hANGPTL3</span>) . تكون الأجسام المضادة البشرية لـ <span dir="LTR">hANGPTL3</span> مفيدة في معالجة أمراض أو اضطرابات مرتبطة بـ <span dir="LTR">ANGPTL3</span> مثل فرط شحوم الدم، وفرط بروتينات الدم الشحمية واختلال الدهون في الدم بما في ذلك فرط ثلاثي الجليسريد في الدم وزيادة الكوليستيرول في الدم وفرط الدقائق الكيلوسية في الدم وما إلى ذلك. بالإضافة الى ذلك، فإن الأجسام المضادة يمكن إعطاؤها لخاضع للعلاج في حاجة للمعالجة للوقاية من أو لمعالجة أمراض أو اضطرابات يكون في أيض الشحم غير الطبيعي بمثابة عامل يسبب الخطورة. تشتمل تلك الامراض او الاضطرابات على أمراض قلبية وعائية مثل التصلب العصيدي ومرض الشريان التاجي والتهاب البنكرياس الحاد والتهاب الكبد الكحولي (<span dir="LTR">NASH</span>) والسكر والسمنة وما شابه ذلك.
JOP/2012/0155A 2011-06-17 2012-06-13 أجسام مضادة ل angptl3 واستخداماتها JO3412B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498518P 2011-06-17 2011-06-17
US201161578309P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
JO3412B1 true JO3412B1 (ar) 2019-10-20

Family

ID=46298728

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0155A JO3412B1 (ar) 2011-06-17 2012-06-13 أجسام مضادة ل angptl3 واستخداماتها

Country Status (46)

Country Link
US (7) US9018356B2 (ar)
EP (2) EP3418301A1 (ar)
JP (2) JP6400471B2 (ar)
KR (1) KR102031007B1 (ar)
CN (1) CN103732624B (ar)
AR (1) AR087329A1 (ar)
AU (1) AU2012271663B2 (ar)
CA (1) CA2838867C (ar)
CL (1) CL2013003552A1 (ar)
CO (1) CO6821892A2 (ar)
CR (1) CR20130621A (ar)
CY (2) CY1120996T1 (ar)
DK (1) DK2721065T3 (ar)
DO (1) DOP2013000299A (ar)
EC (1) ECSP13013085A (ar)
ES (1) ES2699499T3 (ar)
FI (1) FIC20210028I1 (ar)
FR (1) FR21C1061I2 (ar)
GT (1) GT201300306A (ar)
HR (1) HRP20182098T1 (ar)
HU (1) HUS2100034I1 (ar)
IL (2) IL229612B (ar)
JO (1) JO3412B1 (ar)
LT (2) LT2721065T (ar)
LU (1) LUC00231I2 (ar)
MA (1) MA35190B1 (ar)
MX (2) MX337644B (ar)
MY (1) MY160516A (ar)
NI (1) NI201300136A (ar)
NL (1) NL301122I2 (ar)
NO (2) NO2021037I1 (ar)
PE (1) PE20141166A1 (ar)
PH (1) PH12013502570B1 (ar)
PL (1) PL2721065T3 (ar)
PT (1) PT2721065T (ar)
RS (1) RS58310B1 (ar)
RU (1) RU2620064C2 (ar)
SG (1) SG195165A1 (ar)
SI (1) SI2721065T1 (ar)
SM (1) SMT201800658T1 (ar)
TR (1) TR201816591T4 (ar)
TW (3) TW201815822A (ar)
UA (1) UA114891C2 (ar)
UY (2) UY39340A (ar)
WO (1) WO2012174178A1 (ar)
ZA (1) ZA201308879B (ar)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
IL260931B2 (en) * 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
MA43734A (fr) * 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
PL3439689T3 (pl) * 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
MD3448426T2 (ro) * 2016-04-28 2025-09-30 Regeneron Pharma Metode de tratament al pacienților cu hipercolesterolemie familială
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CA3085177A1 (en) 2018-01-31 2019-08-08 Regeneron Pharamaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
AU2019227531B2 (en) 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020047067A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN113396158A (zh) * 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
JP2022517720A (ja) 2019-01-16 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ジスルフィド結合を特徴付けるための方法
WO2020185952A1 (en) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Cd27-binding antibodies and uses thereof
JP7541534B2 (ja) 2019-05-13 2024-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
US12559551B2 (en) * 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR20260058863A (ko) 2019-09-24 2026-04-29 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
WO2021147984A1 (zh) 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 抗angptl3抗体及其应用
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
IL303675A (en) 2020-12-17 2023-08-01 Regeneron Pharma Production of protein thermal microgels
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
TW202246325A (zh) 2021-03-03 2022-12-01 美商再生元醫藥公司 用於定量及修飾蛋白質黏度之系統及方法
WO2022187353A1 (en) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
WO2022205021A1 (zh) * 2021-03-30 2022-10-06 复旦大学附属儿科医院 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
AU2022314036A1 (en) * 2021-07-21 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
EP4413364A2 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
EP4453210A1 (en) * 2021-12-22 2024-10-30 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
AU2023264772A1 (en) 2022-05-02 2024-10-24 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白
CN116143919B (zh) * 2022-11-01 2025-06-13 中国药科大学 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
WO2024130165A1 (en) * 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
JP2026514305A (ja) 2023-05-01 2026-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
EP4780828A2 (en) 2023-09-18 2026-07-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
CN122138969A (zh) 2023-10-18 2026-06-02 瑞泽恩制药公司 从过程中上游细胞培养物材料中快速纯化单克隆抗体
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
CN117551204A (zh) * 2023-11-10 2024-02-13 中国药科大学 一种靶向pcsk9和angptl3的双特异性抗体及其制备方法与应用
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
TW202600593A (zh) 2024-02-16 2026-01-01 美商再生元醫藥公司 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same
WO2026112457A2 (en) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof
WO2026136650A1 (en) 2024-12-20 2026-06-25 Regeneron Pharmaceuticals, Inc. Fixed seed train schedule for improved protein production

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
NZ527408A (en) 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
KR20100029861A (ko) * 2001-11-16 2010-03-17 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
PL1962895T3 (pl) 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CA2664343C (en) * 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CA2839573A1 (en) * 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
PL3087183T3 (pl) 2013-12-24 2021-01-11 Ionis Pharmaceuticals, Inc. Modulacja ekspresji białka angiopoetynopodobnego 3
WO2015168589A2 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
IL260931B2 (en) 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
PL3439689T3 (pl) 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
MD3448426T2 (ro) 2016-04-28 2025-09-30 Regeneron Pharma Metode de tratament al pacienților cu hipercolesterolemie familială
US12559551B2 (en) * 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Also Published As

Publication number Publication date
CY2021036I1 (el) 2022-03-24
PL2721065T3 (pl) 2019-02-28
MX361859B (es) 2018-12-18
JP6400471B2 (ja) 2018-10-03
NO2025028I1 (no) 2025-06-13
CY2021036I2 (el) 2022-05-27
EP3418301A1 (en) 2018-12-26
TWI644922B (zh) 2018-12-21
TW201815822A (zh) 2018-05-01
US20220403016A1 (en) 2022-12-22
US20130171149A1 (en) 2013-07-04
IL229612A0 (en) 2014-01-30
CL2013003552A1 (es) 2014-07-25
EP2721065B1 (en) 2018-09-12
AU2012271663A1 (en) 2014-01-16
IL259436A (en) 2018-07-31
PE20141166A1 (es) 2014-09-16
EP2721065A1 (en) 2014-04-23
GT201300306A (es) 2015-03-09
US20150197564A1 (en) 2015-07-16
US9018356B2 (en) 2015-04-28
LT2721065T (lt) 2018-12-10
NI201300136A (es) 2014-05-15
RU2620064C2 (ru) 2017-05-22
JP2018166516A (ja) 2018-11-01
WO2012174178A1 (en) 2012-12-20
US20220153825A1 (en) 2022-05-19
UY34137A (es) 2013-01-03
LTPA2021009I1 (ar) 2021-09-27
CN103732624B (zh) 2016-08-17
JP2014523739A (ja) 2014-09-18
ES2699499T3 (es) 2019-02-11
TR201816591T4 (tr) 2018-11-21
TW201313738A (zh) 2013-04-01
KR102031007B1 (ko) 2019-11-08
CO6821892A2 (es) 2013-12-31
US10358487B2 (en) 2019-07-23
CN103732624A (zh) 2014-04-16
HUS2100034I1 (hu) 2021-10-28
NZ619092A (en) 2016-03-31
TW201920261A (zh) 2019-06-01
NL301122I2 (nl) 2021-12-30
CR20130621A (es) 2014-02-12
HRP20182098T1 (hr) 2019-02-08
CA2838867C (en) 2020-07-14
LUC00231I2 (ar) 2025-02-03
MY160516A (en) 2017-03-15
US9951127B2 (en) 2018-04-24
DK2721065T3 (en) 2018-12-03
NO2021037I1 (no) 2021-09-15
PT2721065T (pt) 2018-12-06
UY39340A (es) 2021-08-31
AU2012271663B2 (en) 2017-04-20
KR20140037218A (ko) 2014-03-26
CY1120996T1 (el) 2019-12-11
FIC20210028I1 (fi) 2021-09-09
SG195165A1 (en) 2013-12-30
MA35190B1 (fr) 2014-06-02
CA2838867A1 (en) 2012-12-20
SI2721065T1 (sl) 2018-12-31
PH12013502570A1 (en) 2014-01-27
FR21C1061I2 (fr) 2022-11-18
DOP2013000299A (es) 2014-04-15
MX2013014345A (es) 2014-01-31
IL229612B (en) 2019-06-30
LTC2721065I2 (ar) 2022-10-25
MX337644B (es) 2016-03-14
UA114891C2 (uk) 2017-08-28
RS58310B1 (sr) 2019-03-29
US20190092845A1 (en) 2019-03-28
US20190315851A1 (en) 2019-10-17
ECSP13013085A (es) 2014-01-31
ZA201308879B (en) 2014-07-30
PH12013502570B1 (en) 2019-01-16
AR087329A1 (es) 2014-03-19
SMT201800658T1 (it) 2019-01-11
RU2013155906A (ru) 2015-07-27
NL301122I1 (ar) 2021-09-01
US20250136675A1 (en) 2025-05-01
FR21C1061I1 (fr) 2022-01-21

Similar Documents

Publication Publication Date Title
CY1120996T1 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
BR112012017765A2 (pt) anticorpos humanos para proteína semelhante à angiopoietina humana-4
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
UA116194C2 (uk) Антитіло, яке специфічно зв&#39;язується з людським альфа-синуклеїном
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
WO2011111966A3 (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
MA44764A (fr) Méthodes de traitement de patients présentant une hypercholestérolémie familiale
BR112014029219A8 (pt) moléculas de ligação de il-6
BR112015012708A2 (pt) anticorpos para bmp-6
EA201300131A1 (ru) Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
IL213213A (en) Use of Human Monoclonal Antibodies or Antigen-Related Fragments Specific to Human Ligand Protein Protein in the Manufacture of Medicines to Prevent and / or Treat Pampigos
TN2013000490A1 (en) Anti-angptl3 antibodies and uses thereof
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
BR112013026896A2 (pt) métodos e composições adequadas para prevenir e tratar hiperleptinemia
PH12012501279A1 (en) Human antibodies to human angiopoietin-like protein 4
TH147852A (th) แอนติบอดี้ชนิดต้าน angptl3 และการใช้ประโยชน์ของมัน
Brunzell 1516 LIPID AND GLUCOSE TARGETS IN DIABETES AND FAMILIAL COMBINED HYPERLIPIDEMIA
EP2412375A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION BZW. TREATMENT OF DISEASES RELATED TO LIFESTYLE AND FOOD FOR PREVENTION TREATMENT OF DISEASES IN CONNECTION WITH LIFESTYLE